Adam Vogel PhD is Professor of Speech Neuroscience at The University of Melbourne where he leads research to improve communication and swallowing in people with neurological conditions, alongside clinical roles in specialist ataxia and dementia clinics.

He is also CEO of Redenlab Ltd., a US-Australian medtech developing speech and language biomarkers to support decision making in clinical trials, health research, and patient monitoring.